#United States #Chicago #Clinical Trials #Thurston Group #Sensorium Clinical Research

Introduction

Thurston Group, a private equity firm with a focus on healthcare, has recently unveiled a noteworthy initiative by establishing Sensorium Clinical Research. This newly formed clinical trial site network aims to enhance the landscape of clinical trials across the United States by forging partnerships with top-tier clinical research facilities.

Formation of Sensorium Clinical Research

The foundation of Sensorium is significant, as it integrates three distinguished clinical research sites located in California and Florida: Apex Clinical Research, Galiz Research, and Quantum Laboratories. Together, these partners boast over 75 years of collective experience in clinical research, having successfully completed upwards of 400 trials concentrated on crucial therapeutic areas, such as central nervous system conditions, respiratory issues, metabolic disorders, and more. Their established relationships with leading sponsors and contract research organizations (CROs) attest to their dedication to rigorous research and high-quality patient care.

Strategic Vision

The Managing Partner of Thurston Group, Dan Davis, articulated the alignment of this project with the firm’s commitment to partnering with industry leaders in promising, high-growth healthcare sectors. Davis expressed that "Sensorium symbolizes an exciting opportunity to build a premier clinical trial site network that integrates Thurston’s operational acumen with exceptional clinical research capabilities."

The sentiment is echoed by Dana Hayes III, a principal at Thurston Group, who remarked on the pivotal moment for the clinical research industry. As sponsors and CROs emphasize site quality, patient access, and operational dependability, Sensorium is strategically poised to distinguish itself as a valuable partner in this domain.

Leadership and Operational Strategies

To spearhead the initiatives at Sensorium, Matt Kiernan has been appointed as the Chief Executive Officer. With a hefty background of over two decades in clinical research, Kiernan has previously founded and managed successful firms, including Intrinsic Clinical Systems and Pharmica Consulting. His leadership experience also extends to reputable organizations such as Bristol Myers Squibb and Merck, which adds gravitas to Sensorium’s future endeavors.

Under his direction, Sensorium is set to implement a dynamic growth strategy. This strategy emphasizes continuously aligning with outstanding clinical research sites across the U.S., focusing on areas that promise high therapeutic value and fostering strong relationships with sponsors.

Thurston Group’s Legacy

Founded in 1986, Thurston Group has a long-standing history in creating industry-leading companies within the healthcare services sector. Under the leadership of Patrick J. Haynes III, the firm has successfully returned over $4 billion in invested capital over its 40-year journey. Their successful track record includes partnerships with notable companies such as Smile Doctors and U.S. Orthopaedic Partners.

Thurston Group showcases an impressive capability in scaling multi-site healthcare businesses while preserving the critical components like clinical autonomy and physician leadership that are essential to successful research execution.

Conclusion

Sensorium Clinical Research emerges as a promising player in the healthcare landscape, embodying a robust foundation built on expertise, commitment, and strategic insight. As the clinical research industry evolves, Sensorium is dedicated to meeting the demands of the sector while providing top-quality service to sponsors and patients alike. For those interested in the future of clinical trials and research, Sensorium represents not only an opportunity for growth but a beacon of innovation in the healthcare sector. For more details about Sensorium Clinical Research or Thurston Group, please visit their official websites.